Search

Your search keyword '"K. Yoshino"' showing total 47 results

Search Constraints

Start Over You searched for: Author "K. Yoshino" Remove constraint Author: "K. Yoshino" Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
47 results on '"K. Yoshino"'

Search Results

2. Troponin-guided utilization of methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor-related myocarditis.

3. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study.

4. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.

5. Sentinel lymph node biopsy in extramammary Paget disease: A 13-year institutional experience.

6. Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker for extramammary Paget disease: A retrospective study.

7. Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).

8. Helicobacter bilis infection induces oxidative stress in and enhances the proliferation of human cholangiocytes.

9. Emergency aortic valve replacement complicated by unmanaged pheochromocytoma.

10. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.

13. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.

14. Bone metastases could be predictive factors of central nervous system metastases in extramammary Paget's disease.

15. Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib.

17. Successful outcome of early ambulation after extensive skin grafting in extramammary Paget's disease.

18. Case of successfully switching from nivolumab to vemurafenib with oral corticosteroids.

19. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.

21. Nivolumab therapy before vemurafenib administration induces a severe skin rash.

22. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.

25. Severe rash associated with vemurafenib administration following nivolumab therapy.

26. Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease.

27. Hepatitis C virus NS5A protein interacts with lysine methyltransferase SET and MYND domain-containing 3 and induces activator protein 1 activation.

28. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.

29. Perspectives on a new educational system for dental hygiene students in Japan.

30. Neuronal mechanism of mirror movements caused by dysfunction of the motor cortex.

31. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs.

32. Properties and plasticity of the primate somatosensory and motor cortex related to orofacial sensorimotor function.

33. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.

34. In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2.

35. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.

36. An analysis of factors influencing the isolation rate of herpes simplex virus.

38. Differences in the biochemical activity in hairless mouse skin and other organs after systemic and topical methotrexate treatment.

40. Studies on the neutralization of herpes simplex virus. XI. Differences between slow-reacting complement-requiring neutralizing (s-CRN) antibodies in IgG and IgM.

42. Studies on the neutralization of herpes simplex virus. X. Demonstration of complement-requiring neutralizing (CRN) and slow-reacting CRN (s-CRN) antibodies in late IgG.

43. A micro-neutralization system for detection of s-CRN antibody to herpes simplex virus.

44. Studies on the neutralization of herpes simplex virus. VIII. Significance of viral sensitization for inactivation by complement.

46. Estimation of type-specific neutralizing antibody to herpes simplex virus type 2 in uterine cervical cancer patients by a new absorption method.

47. A new microplate neutralization test for typing of herpes simplex virus.

Catalog

Books, media, physical & digital resources